Bone marrow-derived mononuclear cells for acute myocardial infarction

This study aims to assess the efficacy of concentrated bone marrow-derived mononuclear cells enriched in progenitor cells (BMCePC), processed by point of care technology, in improving cardiac function in acute myocardial infarction patients. The cells are administered directly into the infarct-related artery using the stop-flow method and treatment was found to be safe. Treatment improves the patient's Left Ventricular Ejection Fraction ("LVEF") from 35% to 60.3% in 24 months while preventing further infarct scarring and undesirable remodeling.